Navigation Links
Additional Data From Multiple Phase 1 and 2 Studies of S*BIO's Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
Date:6/1/2011

hose with thrombocytopenia.16th Congress of EHAPoster No. 907 (5:30-6:45 p.m. BST, Saturday, June 11)Long-Term Safety and Efficacy Analysis of the Two Phase 1 Studies of SB1518, a Novel Oral JAK2 Inhibitor, in Patents With Advanced Myeloid Malignancies

SB1518 shows promising efficacy in MF patients with splenomegaly. Once-daily dosing is well tolerated to 29 months, with manageable GI toxicity as the main AE. SB1518 does not appear to cause myelosuppression; patients with significantly impaired hematopoiesis can receive full-dose daily SB1518 without exacerbating hematocytopenias. Sixty-three patients were consented and enrolled; 39 (62%) were men, and median age was 65.5 years. Fifty-six had MF, and 7 had AML. Median time on study is 13.3 months (1-29+). As of January 2011, 21 MF patients remain on study. The most common treatment-related AEs were gastrointestinal, which were generally low grade and manageable. These events occurred after 5.7-18.5 months on study. Two patients were discontinued for these AE's and one continues on study at 200 mg dose. Fifteen patients had dose reductions, most within the first 6 months; of these, 11 (73%) started treatment at >500 mg/d. No patients discontinued study medication because of a dose-limiting toxicity. No long-term toxicities were identified. Forty-one MF patients had palpable baseline splenomegaly >5 cm and were evaluable for spleen response. Overall, 39 (70%) of the 56 MF patients experienced CI or stable disease. Among all enrolled patients, duration of progression-free survival (PFS) ranged from 1 to 875 days (median, 563 days), with an estimated 67% rate of PFS at 12 months (Kaplan-Meier).Presentation No. 1022 (8:30-8:45 a.m. BST, Sunday, June 12)Phase 2 Study of SB1518, a Novel Oral JAK2 Inhibitor, in Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis

SB1518 showed promising
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Additional Data From QNEXA Clinical Trials Presented at the European Congress on Obesity
2. Hope Paige Designs Medical ID Bracelets Now Available in 1,100 Additional Locations
3. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
4. Omeros Reports Allowance of Additional Patent for Arthroscopic Product
5. Cynosure Receives Additional International Regulatory Approvals for New Cellulite Reduction Workstations
6. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
7. Rosetta Genomics Announces Issuance of Additional U.S. Patent
8. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
9. Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck
10. Southern Home Medical Equipment Reports Additional Revenues and Profits for 2010
11. Additional 8 Products of DK Sinopharma, Inc. are Included in 2010 Provincial Medical Insurance Catalogs in 4 Separate Provinces in the Peoples Republic of China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 The American Association ... Medical Design and Manufacturing has joined the AAHomecare Corporate ... Harvey Diamond have been actively involved in ... as it has quickly grown into a major global ... like Drive allows AAHomecare to increase efforts on behalf ...
(Date:9/19/2014)... UBM Medica US announces that  ... help oncologists and other clinicians gain a better understanding ... targeted therapies and immunotherapies, discusses some of the latest ... Every September, Blood Cancer Awareness Month ... blood cancers—helping to increase survival rates and improve the ...
(Date:9/19/2014)... WOONSOCKET, R.I. , Sept. 19, 2014 ... (NYSE: CVS ), will speak before the National ...  Merlo will discuss the company,s recent move to stop selling ... to shape the future of health. "Dramatic changes ... consumers, health care providers and government," Merlo has said. "CVS ...
Breaking Medicine Technology:Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
... Dec. 1, 2011 Arbor Pharmaceuticals announced today that it ... the U.S. Food and Drug Administration (FDA).  The recently ... the FDA which provides seven years of market exclusivity. ... status for this product primarily due to the safety ...
... Novelos Therapeutics, Inc. (OTCBB: NVLT) , a pharmaceutical company ... announced the pricing of an underwritten public offering of 9,840,000 ...  Each unit consists of one share of common stock and ... warrants will have an exercise price of $0.60 per share ...
Cached Medicine Technology:Arbor Pharmaceuticals Announces Filing of First NDA 2Novelos Therapeutics Prices $5.9 Million Public Offering 2
(Date:9/21/2014)... New York (PRWEB) September 21, 2014 ... continue to move forward in Pennsylvania’s Philadelphia Court ... to court documents, the proceeding’s next monthly meeting ... Litigation, case number 100300296) , “Our Firm is ... Risperdal lawsuits in this litigation. We are pleased ...
(Date:9/21/2014)... 2014 Best Cheap Hosting USA, one ... Arvixe, Bluehost and GreenGeeks are the best Reseller hosting ... good reseller hosting supplier. Actually, these companies have outperformed ... customer support. People can get the best web hosting ... , According to the manager, reseller hosting is a ...
(Date:9/21/2014)... September 21, 2014 Market ... (CAS 49562-28-9) Industry, 2009-2019 is a professional ... Chinese Fenofibrate (CAS 49562-28-9) industry. The report ... (CAS 49562-28-9) including its classification, application and ... China’s top manufacturers of Fenofibrate (CAS 49562-28-9) ...
(Date:9/21/2014)... September 21, 2014 More than ... been added over the past month to a ... serious cardiovascular injuries caused by the dialysis concentrate, ... updated on September 15th shows 2,089 cases filed ... District Court, District of Massachusetts. These claims were ...
(Date:9/21/2014)... Recently, BambooIndustry.com, an experienced producer of natural bamboo items, ... ( http://www.bambooindustry.com/products/bamboo-panel/ ). The company’s excellent panels are very ... at discounted prices now, from 10 to 30 percent ... are available in many specifications; they are promised ... is finely manufactured by qualified workers. They are specially ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4Health News:Best Cheap Hosting USA Announces The Best Reseller Hosting Suppliers In 2014 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 4Health News:Discounted Bamboo Panels For Sale At BambooIndustry.com 2
... in four teenagers who had meningitis during infancy will not ... in Archives of Disease in Childhood. ,The findings ... year olds across England and Wales, 461 of whom had ... ,The children were all taking part in a long ...
... Scientists of University College London have conducted a study ... is indeed responsible// for dyscalculia or in ... hope the findings will aid in the diagnosis and ... ,Dyscalculia is just as prevalent in the population as ...
... the Victorian disease tuberculosis is on the march. Figures released by ... percent in number of TB cases over the last year. ... on the 24th of March, are provisional and relate ... account for the highest proportion of cases (42 percent) but the ...
... Steriani Elavsky, women passing through their menopause are reported to ... improvements in heart and respiratory fitness are said to have ... ,This research was carried out on 164 inactive menopausal ... basis. One group was assigned to perform Yoga while the ...
... junior doctors' has been reduced in order to increase their ... medics found that cutting down working hours alone is not ... of rotas was essential. ,The Occupational and Environmental ... Auckland universities in New Zealand. ,In the UK, ...
... that the odds of firefighters dying from coronary heart disease ... 100 times higher than during non-emergency duties such as rescuing ... Harvard Medical School and colleagues say episodic physical and psychological ... of physical fitness appeared responsible for it. ,Even though ...
Cached Medicine News:Health News:Reason Behind Dyscalculia Revealed 2Health News:TB Cases on the Rise 2Health News:Rest for Doctors to Ensure Patients’ Safet 2Health News:New Study Reveals That Firefighters Are Prone To Heart Attack 2
... The D.O.R.C. Associate® is an ... a Peristaltic and Venturi pump, allowing ... mode for Phaco or Vitrectomy procedures.,The ... is a microprocessor-controlled vacuum system that ...
The D.O.R.C. CryoStar is the smart cryosurgical system that combines optimal performance with state-of-the-art automation. simple for O.R. staff to operate and maintain throughout every procedure....
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media.(Sterile, 10 ml.)...
Medicine Products: